Crucell peps up
Leiden – Crucell N.V. has signed an agreement with Pepscan Therapeutics to use its protein mimicry technology to develop vaccines to treat undisclosed infectious diseases. Pepscan’s Chemical Linkage of Peptides onto Scaffolds (CLIPS) technology presents one or more linear peptides in a structurally constrained configuration to increase biological activity. Pepscan will receive research funding, and is eligible for milestones and royalties. Further financial details were not disclosed. Meanwhile, the takeover of Crucell has moved forward since US pharmaceuticals giant Johnson & Johnson bought the Leiden-based vaccine specialist for EUR1.75bn in February. It now controls almost 99% of the shares outstanding, and the US firm is set to embark on a buy-out procedure to mop up the remaining shares.